BeOne Medicines Ltd. (ONC)
NASDAQ: ONC · Real-Time Price · USD
307.51
+19.41 (6.74%)
Aug 13, 2025, 4:00 PM - Market closed
BeOne Medicines Employees
BeOne Medicines had 11,000 employees as of December 31, 2024. The number of employees increased by 400 or 3.77% compared to the previous year.
Employees
11,000
Change (1Y)
400
Growth (1Y)
3.77%
Revenue / Employee
$414,727
Profits / Employee
-$16,149
Market Cap
33.83B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11,000 | 400 | 3.77% |
Dec 31, 2023 | 10,600 | 1,600 | 17.78% |
Dec 31, 2022 | 9,000 | 1,000 | 12.50% |
Dec 31, 2021 | 8,000 | 2,700 | 50.94% |
Dec 31, 2020 | 5,300 | 1,800 | 51.43% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ONC News
- 7 days ago - BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates - Business Wire
- 13 days ago - BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom's Macroglobulinemia - Business Wire
- 16 days ago - BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment - Business Wire
- 4 weeks ago - BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6 - Business Wire
- 4 weeks ago - European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma - Business Wire
- 5 weeks ago - Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development - Business Wire
- 6 weeks ago - BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day - Business Wire